Abstract
An accurate and very sensitive spectrofluorimetric method is proposed for the estimation of heptaminol (HP) and mexiletine (MX) in their pure forms and in pharlnaceutical formulations. The method is based on the reaction of these drugs with the strong fluorigenic reagent [9,1O-Dimethoxy-2-anthracenesulfonic acid sodium salt (DAS)] at pH (2.5). The formed complexes are extracted into chloroform and measured spectrofluori~netrically. The maximum wavelengths of excitation and emission spectra of heptaminol complex are 381 and 441 m, respectively. While those of mexiletine complex are 385 and 450 nrn, respectively. Heptaminol can be determined in the concentration range of 0.016-0.144 µg ml−1 and that of mexiletine in the range of 0.024-0.176 µg ml−1, when extracted from the solutions into chloroform. Different parameters affecting the reaction conditions were thoroughly studied. No interference was observed in the presence of common pharmaceutical excipients. The proposed method has been successfully applied to the analysis of commercial pharmaceutical fonnulations and the results have been statistically compared with those obtained by the reference methods.
Highlights
Heptaminol (HP) and Mexiletine (MX) are cardiovascular drugs containing an aliphatic primary amino group in their structures
Procedures: Standard solution preparations: HP and MX were prepared as a stock solution of 0.5 mg.ml-' by dissolving 50 mg of HP and MX hydrochlorides in a 100 ml volumetric flask with completion to the mark with de-ionized water
Determination of pharmaceutical formulations: An accurately weighed quantity of either tablet's powder (Corasore tablets containing HP-HCl) or capsule's powder (Mexitil capsules containing MX-HCl) equivalent to 50 mg of each drug was quantitatively transferred to 100-ml volumetric flask
Summary
Heptaminol (HP) and Mexiletine (MX) are cardiovascular drugs containing an aliphatic primary amino group in their structures. Procedures: Standard solution preparations: HP and MX were prepared as a stock solution of 0.5 mg.ml-' by dissolving 50 mg of HP and MX hydrochlorides in a 100 ml volumetric flask with completion to the mark with de-ionized water. The combined chloroformic extracts were filtered through anhydrous sodium sulfate into a 25 ml volumetric flasks and completed to volume with the same solvent. Determination of pharmaceutical formulations: An accurately weighed quantity of either tablet's powder (Corasore tablets containing HP-HCl) or capsule's powder (Mexitil capsules containing MX-HCl) equivalent to 50 mg of each drug was quantitatively transferred to 100-ml volumetric flask. 1 ml of the filtrate of each drug was transferred into a 250 ml volumetric flask and the volume was completed to the mark with de-ionized water. An aliquot portions of the final solution were transferred into a dry series of 50-ml separatory funnels and the procedure was completed as mentioned before
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
